BPC-157 — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Cutaneous wound healing and tissue repair
Anchor outcome. Time to complete closure.
Effect as recorded. No randomised controlled human trial identified; —.[1,2]
Certainty. Very low certainty Preclinical only.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for cutaneous wound healing and tissue repair · Indication assessment
§3.2Inflammatory bowel disease and mucosal barrier disorders
Anchor outcome. Clinical remission.
Effect as recorded. A phase 2 programme in ulcerative colitis was conducted and results were not published in a peer-reviewed journal in a form the Institute could verify; not reportable.[2,3]
Certainty. Very low certainty A registered clinical programme existed. The Institute could not locate a peer-reviewed primary publication of its results, and records the non-publication itself as the finding.
Contributing trials. BPC-PH2-UC. Full structured abstracts are published for each.
Full evidence extract for inflammatory bowel disease and mucosal barrier disorders · Indication assessment
§3.3Knee osteoarthritis with obesity
Anchor outcome. WOMAC pain subscale.
Effect as recorded. No randomised controlled human trial identified; —.[3,4]
Certainty. Very low certainty Preclinical only.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for knee osteoarthritis with obesity · Indication assessment
§3.4Tendon, ligament and musculoskeletal soft-tissue injury
Anchor outcome. Time to return to activity.
Effect as recorded. No randomised controlled human trial identified; —.[4,5]
Certainty. Very low certainty The tendon and ligament claims that dominate discussion of this compound rest entirely on rodent models. There is no human trial.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for tendon, ligament and musculoskeletal soft-tissue injury · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632. doi:10.2174/138161211796196954 · PMID 21548867
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.
- Carvalho M, Dinis-Oliveira RJ. Analytical and forensic aspects of counterfeit peptide hormones. Drug Testing and Analysis 2023;15(1):5–19. doi:10.1002/dta.3379
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.